Pfizer Rounds Out Zyrtec Line With Chewable Tablet NDA Approval
This article was originally published in The Tan Sheet
Executive Summary
Pfizer hopes to increase pediatric use of its Rx allergy drug Zyrtec (cetirizine) with new 5 mg and 10 mg chewable tablets formulations, to be available starting in late April and moving to full distribution in early summer